Asarina Pharma AB (publ) reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was SEK 32.93 million compared to SEK 75.26 million a year ago. Basic loss per share from continuing operations was SEK 1.76 compared to SEK 4.02 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.832 SEK | 0.00% | -12.79% | -5.45% |
Feb. 27 | Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-5.45% | 1.74M | |
+5.66% | 111B | |
+11.23% | 105B | |
-12.15% | 22.34B | |
-2.74% | 21.93B | |
-5.80% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- ASAP Stock
- News Asarina Pharma AB
- Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021